

ARES ALLERGY HOLDINGS PLC

ARES ALLERGY HOLDINGS PLC TO HOLD BUSINESS UPDATE ON 5 NOVEMBER 2015 AND ANNOUNCES FINANCIAL REPORTING SCHEDULE

London (United Kingdom), 14 October 2015 – Ares Allergy Holdings plc (the “Company”, Euronext: STAGR) today announces that it will hold a webcast business update, hosted by Chairman and CEO, Fereydoun Firouz, on 5 November 2015. This update will present the company’s corporate strategy and initiatives following the combination of STALLERGENES SA and GREER Laboratories Inc.

The Company also today announces changes to the way it will present its results and its financial calendar for the end of 2015 and beginning of 2016. Following the combination of STALLERGENES SA and GREER Laboratories Inc. the Company is embarking on a new period of development and growth which it believes will be best served by taking a long-term view of the opportunities available to it. In order to align the Company’s reporting schedule more effectively with this approach, the Company will publish financial information at half year intervals. The next financial communication from the Company will therefore be its full year results on 9 March 2016.

ABOUT ARES ALLERGY HOLDINGS PLC

Headquartered in London (UK), Ares Allergy Holdings plc is a global company specialising in the diagnosis and treatment of allergies through the development and commercialization of allergy immunotherapy products and services. Ares Allergy Holdings plc is the parent company of GREER Laboratories, Inc. (whose registered office is in the U.S.) and STALLERGENES SAS (whose registered office is in France).

Trading information:

Name: Stallergenes Greer

ISIN: GB00BZ21RF93 1 - Ticker: STAGR

ICB classification: 4577

Market: Euronext Paris regulated market

Additional information is available at <http://www.aresallergy.com>

Contacts:

Investor and analyst relations

Peter Bühler
Chief Financial Officer
Tel: +33 1 55 59 23 22
Email: investorrelations@aresallergyco.com

Media relations

Lise Lemonnier
Head of Global Communications
Tel: + 33 1 55 59 20 96
Email: llemonnier@stallergenes.com

Investor and Media relations agency:

UK: Robin Wrench, Brunswick Group
Email: aresallergy@brunswickgroup.com
Tel. +44 (0)20 7404 5959